Kuranari Yuki, Tamura Ryota, Tsuda Noboru, Kosugi Kenzo, Morimoto Yukina, Yoshida Kazunari, Toda Masahiro
Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.
Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Front Oncol. 2020 Nov 24;10:592470. doi: 10.3389/fonc.2020.592470. eCollection 2020.
Meningiomas are the most common benign intracranial tumors. However, even WHO grade I meningiomas occasionally show local tumor recurrence. Prognostic factors for meningiomas have not been fully established. Neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic factor for several solid tumors. The prognostic value of NLR in meningiomas has been analyzed in few studies.
This retrospective study included 160 patients who underwent surgery for meningiomas between October 2010 and September 2017. We analyzed the associations between patients' clinical data (sex, age, primary/recurrent, WHO grade, extent of removal, tumor location, peritumoral brain edema, and preoperative laboratory data) and clinical outcomes, including recurrence and progression-free survival (PFS).
Forty-four meningiomas recurred within the follow-up period of 3.8 years. WHO grade II, III, subtotal removal, history of recurrence, Ki-67 labeling index ≥3.0, and preoperative NLR value ≥2.6 were significantly associated with shorter PFS ( < 0.001, < 0.001, 0.002, < 0.001, and 0.015, respectively). Furthermore, NLR ≥ 2.6 was also significantly associated with shorter PFS in a subgroup analysis of WHO grade I meningiomas ( = 0.003). In univariate and multivariate analyses, NLR ≥2.6 remained as a significant predictive factor for shorter PFS in patients with meningioma ( = 0.014).
NLR may be a cost-effective and novel preoperatively usable biomarker in patients with meningiomas.
脑膜瘤是最常见的颅内良性肿瘤。然而,即使是世界卫生组织(WHO)I级脑膜瘤偶尔也会出现局部肿瘤复发。脑膜瘤的预后因素尚未完全明确。中性粒细胞与淋巴细胞比值(NLR)已被报道为几种实体瘤的预后因素。关于NLR在脑膜瘤中的预后价值的研究较少。
这项回顾性研究纳入了2010年10月至2017年9月期间接受脑膜瘤手术的160例患者。我们分析了患者的临床数据(性别、年龄、原发/复发、WHO分级、切除范围、肿瘤位置、瘤周脑水肿和术前实验室数据)与临床结局之间的关联,包括复发和无进展生存期(PFS)。
在3.8年的随访期内,44例脑膜瘤复发。WHO II级、III级、次全切除、复发史、Ki-67标记指数≥3.0以及术前NLR值≥2.6与较短的PFS显著相关(分别为<0.001、<0.001、0.002、<0.001和0.015)。此外,在WHO I级脑膜瘤的亚组分析中,NLR≥2.6也与较短的PFS显著相关(P = 0.003)。在单因素和多因素分析中,NLR≥2.6仍然是脑膜瘤患者较短PFS的显著预测因素(P = 0.014)。
NLR可能是脑膜瘤患者一种具有成本效益且术前可用的新型生物标志物。